April 03, 2013
A Florida federal judge on Tuesday pared multidistrict litigation over Bayer Corp.'s blood-clotting drug Trasylol after finding an expert witness had not properly considered all the necessary information in finding that the drug was responsible for a heart transplant patient's kidney failure and death.
September 13, 2010
Bayer Corp. has persuaded a federal judge to exclude portions of an expert's testimony for plaintiffs in the multidistrict litigation over the company's blood-clotting drug Trasylol.
July 14, 2009
Plaintiffs in the multidistrict litigation over Bayer AG's Trasylol have intensified efforts to obtain an internal report that allegedly discusses dangers associated with the blood-clotting drug.
April 20, 2009
Bayer AG is facing calls by plaintiffs in multidistrict litigation over its blood-clotting drug Trasylol to hand over thousands of documents the pharmaceutical company claims are protected by attorney-client privilege.
March 31, 2009
Bayer AG has asked a judge to expand his dismissal of fraud claims in three suits to include others in the multidistrict litigation over the blood-clotting drug Trasylol, which Bayer pulled from the market after studies indicating potentially fatal side effects came to light.
August 19, 2008
Bayer AG has asked a judge to dismiss fraud claims from a multidistrict lawsuit against the drugmaker over its now-recalled Trasylol, a drug used to reduce blood loss during surgery, saying that the plaintiffs have not pleaded the claim with sufficient particularity.